Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag S/Adr (OP:BAYRY)

13.35 -1.05 (-7.29%)
Streaming Delayed Price Updated: 9:54 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag S/Adr

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
 
Via Benzinga
News headline image
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers ↗
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: Bayer Q4 Earnings ↗
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat... 
Via Benzinga
News headline image
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows ↗
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. 
Via Benzinga
News headline image
Investment Strategy Monthly Insights, April 2022 ↗
After four decades of low inflation, developed economies are grappling with an inflation spike. 
Via Talk Markets
News headline image
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
News headline image
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up? ↗
Merck shares hit a six-month high Tuesday on the bullish projection. 
Via Investor's Business Daily
News headline image
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn ↗
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm. 
Via InvestorPlace
News headline image
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia ↗
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
News headline image
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
News headline image
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer ↗
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022... 
Via Benzinga
News headline image
Why Are Evotec Shares Trading Lower On Friday? ↗
Bayer AG (OTC: BAYRY) has  
Via Benzinga
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
News headline image
Corporate Cannabis Takeover? Assessing 5 Big Industries Already At The Table ↗
This article was originally published on The Bluntness, and ... 
Via Benzinga
News headline image
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities ↗
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY). The expanded... 
Via Benzinga
News headline image
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable ↗
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech. 
Via InvestorPlace
News headline image
Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial ↗
Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical... 
Via Benzinga
News headline image
Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities ↗
Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries... 
Via Benzinga
News headline image
The Secret To Successful Investing In Biotech ↗
Have you ever had a stock jump 30%, 50% or 100% in one day? 
Via Talk Markets
News headline image
Agricultural Technology Companies Are Finding Themselves in a Global Race to Develop and Acquire New Intellectual Property ↗
Image by AgriFORCE The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
Via Benzinga
News headline image
Here’s What Happens When You Beat The Market By 5% (And How To Do It) ↗
See, the way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. And today I want to show you how savvy stock pickers can profit... 
Via Talk Markets
News headline image
I See Another “Chipotle Moment” ↗
Lawsuits are terrible for business. They bring distractions, extra costs, and uncertainty. Big Tobacco knows this all too well. 
Via Talk Markets
Topics Lawsuit
News headline image
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer? ↗
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
News headline image
BWXT Medical, Bayer AG Ink Agreement On Actinium-225 ↗
BWX Technologies Inc's (NYSE: BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC: BAYRY) to develop Actinium-225 (Ac-225) supply and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.